NCT03657966View on ClinicalTrials.gov

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 23, 2017

Primary Completion Date

November 11, 2020

Study Completion Date

February 25, 2021

Conditions

Ovarian Cancer Recurrent

Interventions

BIOLOGICAL

DCVAC/OvCa

activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy

DRUG

Standard of Care Chemotherapy

either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa

Trial Locations (8)

625 00

University Hospital Brno, Brno

656 53

Masaryk Memorial Cancer Institute, Brno

741 01

Hospital Novy Jicin, Nový Jičín

708 52

University Hospital in Ostrava, Ostrava

304 60

University Hospital Plzen, Pilsen

100 34

University Hospital Kralovsko Vinohrady, Prague

128 08

General University Hospital in Prague, Prague

180 81

Hospital Bulovka, Prague

All Listed Sponsors

lead

SOTIO a.s.

INDUSTRY

NCT03657966 - DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter